A 71-year-old woman with multimorbidity attends for a comprehensive medication review. She has atrial fibrillation, heart failure (NYHA II), type 2 diabetes, hypertension, and gastro-oesophageal reflux disease. Her current medications include apixaban 5mg BD, bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, metformin 1g BD, gliclazide 80mg BD, amlodipine 5mg OD, atorvastatin 80mg ON, and omeprazole 20mg OD. Her HbA1c is 48 mmol/mol and she has had three episodes of symptomatic hypoglycaemia in the past 2 months. What is the most appropriate medication modification?
Q62
You are conducting a medication review for a 76-year-old man taking 14 regular medications for multiple conditions including Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression. He reports worsening tremor, confusion, and visual hallucinations over the past month. His daughter mentions he started new medication recently. Which medication is most likely responsible for his deterioration through anticholinergic effects?
Q63
A 74-year-old woman with type 2 diabetes, chronic kidney disease stage 3b (eGFR 34 ml/min/1.73m²), heart failure, and osteoarthritis takes 11 regular medications. She has been prescribed ibuprofen 400mg TDS by a locum GP for worsening knee pain. At her medication review one month later, her eGFR has fallen to 24 ml/min/1.73m² (now CKD stage 4) and she reports ankle swelling. Which medication interaction and mechanism best explains this clinical deterioration?
Q64
A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 40%), and atrial fibrillation takes 12 regular medications. He reports difficulty remembering to take all his medications and admits missing doses several times weekly. His HbA1c has risen from 58 to 72 mmol/mol over 6 months, and his blood pressure is 152/94 mmHg. His renal function is stable (eGFR 52 ml/min/1.73m²). Which intervention has the strongest evidence base for improving medication adherence in patients with multimorbidity and polypharmacy?
Q65
According to current NICE guidance on multimorbidity (NG56), which of the following patients would be most appropriate to offer a structured approach to multimorbidity care including comprehensive assessment and individualized management plan?
Q66
During a structured medication review using the STOPP/START criteria, you assess a 78-year-old man with heart failure (LVEF 38%), type 2 diabetes, benign prostatic hyperplasia, and recurrent lower urinary tract symptoms. His medications include bisoprolol, ramipril, furosemide, spironolactone, metformin, gliclazide, tamsulosin, and tolterodine 4mg BD which was started 3 months ago for urinary urgency. Since starting tolterodine, he reports worsening urinary hesitancy and has not noticed improvement in urgency. What is the most appropriate action according to STOPP/START criteria?
Q67
A 72-year-old woman attends for her annual medication review. She has rheumatoid arthritis, type 2 diabetes, hypertension, and recurrent urinary tract infections. Her current medications include methotrexate 15mg weekly, folic acid 5mg weekly, prednisolone 5mg daily, metformin 1g BD, ramipril 5mg daily, amlodipine 5mg daily, and atorvastatin 40mg at night. She mentions she takes cranberry supplements daily to prevent UTIs. What is the most important medication safety concern to address?
Q68
A 67-year-old man with multimorbidity attends for a medication review. He has type 2 diabetes, ischaemic heart disease, hypertension, and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²). He takes 10 regular medications. He reports feeling dizzy on standing and has had two falls in the past month. His sitting blood pressure is 118/68 mmHg, standing blood pressure 95/55 mmHg. His most recent HbA1c is 48 mmol/mol. Which medication class is the highest priority to review and potentially reduce in this clinical scenario?
Q69
A 70-year-old woman presents for a routine chronic disease review. She has five long-term conditions: type 2 diabetes mellitus, hypertension, osteoarthritis, hypothyroidism, and depression. She takes 9 regular medications and reports good adherence. Her HbA1c is 52 mmol/mol, blood pressure 138/82 mmHg, and she feels generally well. According to current best practice guidance for managing patients with multimorbidity, what is the most appropriate approach to her ongoing care?
Q70
A 75-year-old man with ischaemic heart disease, heart failure (NYHA class II), type 2 diabetes, COPD, and chronic kidney disease stage 3b takes 11 regular medications. During a comprehensive medication review, you use the Medicines Optimisation principles from the Royal Pharmaceutical Society. You have already ensured he understands why he takes each medicine (Principle 1) and that he chooses medicines based on conversations about what matters to him (Principle 2). You are now addressing whether each medicine is working optimally (Principle 3). His recent blood tests show: HbA1c 64 mmol/mol, eGFR 38 ml/min/1.73m², NT-proBNP 680 ng/L (previously 420 ng/L 6 months ago), and BP 146/88 mmHg. Which single parameter most urgently requires medication optimization?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 61: A 71-year-old woman with multimorbidity attends for a comprehensive medication review. She has atrial fibrillation, heart failure (NYHA II), type 2 diabetes, hypertension, and gastro-oesophageal reflux disease. Her current medications include apixaban 5mg BD, bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, metformin 1g BD, gliclazide 80mg BD, amlodipine 5mg OD, atorvastatin 80mg ON, and omeprazole 20mg OD. Her HbA1c is 48 mmol/mol and she has had three episodes of symptomatic hypoglycaemia in the past 2 months. What is the most appropriate medication modification?
A. Stop omeprazole as it interferes with apixaban metabolism
B. Reduce or stop gliclazide and accept slightly higher HbA1c target (Correct Answer)
C. Stop metformin and increase gliclazide to maintain glycaemic control
D. Reduce ramipril dose as it increases risk of hypoglycaemia
E. Add acarbose to reduce post-prandial glucose fluctuations
Explanation: ***Reduce or stop gliclazide and accept slightly higher HbA1c target***
- The patient's **HbA1c of 48 mmol/mol** indicates good glycaemic control, but she is experiencing **symptomatic hypoglycaemia**.
- **Gliclazide**, a sulfonylurea, is a known cause of hypoglycaemia; in elderly patients with **multimorbidity**, relaxing the **HbA1c target** (e.g., to 53–58 mmol/mol) prioritizes safety and reduces hypoglycaemia risk.
*Stop omeprazole as it interferes with apixaban metabolism*
- There is no clinically significant interaction between **omeprazole** and **apixaban** metabolism that would necessitate stopping omeprazole.
- This modification does not address the patient's immediate and dangerous problem of recurrent **hypoglycaemia** and could worsen her **GORD**, especially while on anticoagulants.
*Stop metformin and increase gliclazide to maintain glycaemic control*
- **Metformin** has a low risk of hypoglycaemia and is generally preferred for type 2 diabetes due to its beneficial effects and minimal hypoglycaemia risk.
- Increasing the dose of **gliclazide** would directly worsen the frequency and severity of **hypoglycaemic episodes**, making this modification inappropriate and dangerous.
*Reduce ramipril dose as it increases risk of hypoglycaemia*
- While **ACE inhibitors** like **ramipril** may theoretically increase insulin sensitivity, they are not a primary or common cause of **symptomatic hypoglycaemia**.
- Reducing **ramipril** would be detrimental as it provides essential **cardioprotection** and **renoprotection** for her heart failure, hypertension, and diabetes.
*Add acarbose to reduce post-prandial glucose fluctuations*
- Adding another glucose-lowering agent like **acarbose** increases the complexity of the medication regimen (**polypharmacy**) and does nothing to mitigate the **hypoglycaemia risk** from gliclazide.
- **Acarbose** is often poorly tolerated due to gastrointestinal side effects and is not the recommended intervention for a patient with an already low **HbA1c of 48 mmol/mol** experiencing hypoglycaemia.
Question 62: You are conducting a medication review for a 76-year-old man taking 14 regular medications for multiple conditions including Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression. He reports worsening tremor, confusion, and visual hallucinations over the past month. His daughter mentions he started new medication recently. Which medication is most likely responsible for his deterioration through anticholinergic effects?
A. Tamsulosin for benign prostatic hyperplasia
B. Bisoprolol for hypertension
C. Oxybutynin for urinary urgency (Correct Answer)
D. Metformin for type 2 diabetes
E. Ropinirole for Parkinson's disease
Explanation: ***Oxybutynin for urinary urgency***- **Oxybutynin** is a potent **anticholinergic** agent that readily crosses the blood-brain barrier, leading to **central nervous system** toxicity including **confusion**, **visual hallucinations**, and worsening **tremor**.- In elderly patients, particularly those with **Parkinson's disease**, anticholinergics significantly increase the **anticholinergic burden**, exacerbating cognitive decline and motor symptoms by disrupting cholinergic balance.*Tamsulosin for benign prostatic hyperplasia*- **Tamsulosin** is an **alpha-1 adrenoceptor antagonist** that primarily relaxes smooth muscle in the prostate and bladder neck.- It lacks significant **anticholinergic properties** and is not associated with cognitive impairment, hallucinations, or worsening tremor through anticholinergic mechanisms.*Bisoprolol for hypertension*- **Bisoprolol** is a **beta-1 selective adrenergic blocker** that reduces sympathetic nervous system activity.- It has no significant **muscarinic receptor** antagonism and therefore does not produce the classic **anticholinergic syndrome** of confusion and hallucinations.*Metformin for type 2 diabetes*- **Metformin** is a **biguanide** that reduces hepatic glucose production and improves insulin sensitivity.- Its primary side effects are **gastrointestinal**, and it has no known **anticholinergic activity** or association with cognitive deterioration or hallucinations.*Ropinirole for Parkinson's disease*- **Ropinirole** is a **dopamine agonist** that can cause side effects like **hallucinations** and **confusion**, especially in elderly patients.- However, it would typically **improve** rather than worsen a **tremor** in Parkinson's disease, and its mechanism for cognitive side effects is not through **anticholinergic effects**.
Question 63: A 74-year-old woman with type 2 diabetes, chronic kidney disease stage 3b (eGFR 34 ml/min/1.73m²), heart failure, and osteoarthritis takes 11 regular medications. She has been prescribed ibuprofen 400mg TDS by a locum GP for worsening knee pain. At her medication review one month later, her eGFR has fallen to 24 ml/min/1.73m² (now CKD stage 4) and she reports ankle swelling. Which medication interaction and mechanism best explains this clinical deterioration?
A. NSAID interaction with ACE inhibitor causing acute tubular necrosis
B. NSAID-induced sodium retention worsening heart failure and reducing renal perfusion (Correct Answer)
C. NSAID interaction with metformin causing accumulation and lactic acidosis
D. NSAID inhibition of diuretic action leading to volume overload and pre-renal failure
E. NSAID-induced hyperkalaemia causing cardiac dysfunction and reduced renal blood flow
Explanation: ***NSAID-induced sodium retention worsening heart failure and reducing renal perfusion***
- **NSAIDs** inhibit **prostaglandin synthesis**, which causes **sodium and water retention**, explaining the patient's new-onset **ankle swelling** and heart failure exacerbation.
- Reduced **renal perfusion** due to worsened heart failure and the loss of prostaglandin-mediated **afferent arteriolar vasodilation** leads to a significant fall in **eGFR**.
*NSAID interaction with ACE inhibitor causing acute tubular necrosis*
- While the combination with an **ACE inhibitor** (part of the "triple whammy") causes **haemodynamic acute kidney injury**, it typically results from **pre-renal** changes rather than **acute tubular necrosis**.
- This explanation focuses on a structural injury, whereas the clinical presentation and **ankle swelling** point toward **fluid retention** and haemodynamic decline.
*NSAID interaction with metformin causing accumulation and lactic acidosis*
- **NSAIDs** do not have a direct pharmacological interaction with **metformin**, although they can indirectly cause metformin accumulation by reducing **renal clearance**.
- The patient presents with **oedema** and a drop in **eGFR**, not the systemic symptoms of **metformin-associated lactic acidosis** (e.g., abdominal pain, tachypnea).
*NSAID inhibition of diuretic action leading to volume overload and pre-renal failure*
- **NSAIDs** do antagonize the effects of **diuretics** by reducing renal blood flow and interfering with **prostaglandin-dependent natriuresis**.
- While this contributes to **volume overload**, the primary mechanisms for the **eGFR** drop in this complex patient are the direct **renal haemodynamic** changes and worsened cardiac output.
*NSAID-induced hyperkalaemia causing cardiac dysfunction and reduced renal blood flow*
- **NSAIDs** can cause **hyperkalaemia** by suppressing **renin and aldosterone** secretion, but this is rarely the primary driver of a 10 ml/min drop in **eGFR**.
- **Cardiac dysfunction** in this scenario is driven by **fluid overload** and increased **afterload** due to systemic vasoconstriction, rather than potassium-induced arrhythmias.
Question 64: A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 40%), and atrial fibrillation takes 12 regular medications. He reports difficulty remembering to take all his medications and admits missing doses several times weekly. His HbA1c has risen from 58 to 72 mmol/mol over 6 months, and his blood pressure is 152/94 mmHg. His renal function is stable (eGFR 52 ml/min/1.73m²). Which intervention has the strongest evidence base for improving medication adherence in patients with multimorbidity and polypharmacy?
A. Arranging for a pharmacist-led structured medication review addressing barriers to adherence (Correct Answer)
B. Setting up a monitored dosage system (dosette box) for medication administration
C. Increasing the frequency of GP appointments to monthly reviews for reinforcement
D. Providing written information leaflets about each medication and its importance
E. Switching to combination tablets wherever possible to reduce pill burden
Explanation: ***Arranging for a pharmacist-led structured medication review addressing barriers to adherence*** - **Pharmacist-led structured medication reviews** are evidence-based interventions specifically designed to identify and address individual **barriers to adherence**, whether intentional (e.g., side effects) or unintentional (e.g., forgetfulness or complexity) in patients with **multimorbidity** and **polypharmacy**. - This personalized approach allows for tailored solutions, such as simplifying regimens, adjusting timing, or addressing patient concerns, leading to significant improvements in adherence and clinical outcomes like **HbA1c** and **blood pressure**. *Setting up a monitored dosage system (dosette box) for medication administration* - While helpful for some patients, **monitored dosage systems** primarily aid in organizing medications and do not inherently address the underlying **cognitive or behavioral barriers** to adherence. - The evidence base for dosette boxes as a standalone intervention for improving long-term adherence or clinical outcomes in complex patients with **polypharmacy** is surprisingly weak. *Increasing the frequency of GP appointments to monthly reviews for reinforcement* - More frequent GP appointments mainly focus on **monitoring clinical parameters** and general health advice, which may not directly target the specific challenges of medication adherence. - This approach can increase the **treatment burden** on the patient and may not provide the detailed, patient-specific medication counseling required for managing **polypharmacy**. *Providing written information leaflets about each medication and its importance* - **Written information** alone is largely ineffective for improving long-term medication adherence, especially in older patients managing a large number of medications. - This passive method does not facilitate the crucial **dialogue** needed to uncover patient-specific barriers or misunderstandings about their complex medication regimen. *Switching to combination tablets wherever possible to reduce pill burden* - Reducing **pill burden** through combination tablets simplifies the regimen, which can be beneficial, but it does not address other critical factors like **forgetfulness**, side effects, or patient beliefs that contribute to non-adherence. - While a good adjunctive strategy, it lacks the comprehensive, **individualized assessment** and support offered by a structured medication review for multifactorial adherence issues.
Question 65: According to current NICE guidance on multimorbidity (NG56), which of the following patients would be most appropriate to offer a structured approach to multimorbidity care including comprehensive assessment and individualized management plan?
A. A 58-year-old man with well-controlled hypertension and type 2 diabetes
B. A 73-year-old woman with COPD, heart failure, and depression causing significant functional impairment (Correct Answer)
C. A 65-year-old man with three chronic conditions all well controlled on stable treatment
D. A 45-year-old woman with asthma and hypothyroidism managed in specialist clinics
E. A 70-year-old man with hypertension, hyperlipidaemia, and osteoarthritis who manages independently
Explanation: ***A 73-year-old woman with COPD, heart failure, and depression causing significant functional impairment***- According to **NICE NG56**, a structured management plan is indicated for patients with multiple conditions that result in **significant functional impairment** or high healthcare utilization.- The combination of **COPD, heart failure, and depression** represents high complexity where diseases and treatments frequently interact, requiring an **individualized management plan**.*A 58-year-old man with well-controlled hypertension and type 2 diabetes*- Patients with **well-controlled** chronic conditions do not automatically require the intensive structured approach if their current care is meeting their needs.- The focus for this patient remains on standard **routine monitoring** rather than a comprehensive, multidisciplinary multimorbidity assessment.*A 65-year-old man with three chronic conditions all well controlled on stable treatment*- The **number of conditions** alone does not trigger the NG56 structured approach; it is the impact on **quality of life** and care complexity that matters.- Since this patient is on **stable treatment** and well-controlled, the burden of multimorbidity is currently considered low.*A 45-year-old woman with asthma and hypothyroidism managed in specialist clinics*- Management in **specialist clinics** suggests that her current care arrangements are effectively addressing her specific medical needs.- There is no evidence of **functional impairment** or difficulty in managing the treatment burden that would necessitate a primary care-led multimorbidity review.*A 70-year-old man with hypertension, hyperlipidaemia, and osteoarthritis who manages independently*- **Managing independently** is a key indicator that the patient's current health status does not require a formal, resource-intensive structured assessment.- While he has multimorbidity, the lack of **frequent unplanned care** or significant functional loss means he does not meet the priority criteria for NG56 intervention.
Question 66: During a structured medication review using the STOPP/START criteria, you assess a 78-year-old man with heart failure (LVEF 38%), type 2 diabetes, benign prostatic hyperplasia, and recurrent lower urinary tract symptoms. His medications include bisoprolol, ramipril, furosemide, spironolactone, metformin, gliclazide, tamsulosin, and tolterodine 4mg BD which was started 3 months ago for urinary urgency. Since starting tolterodine, he reports worsening urinary hesitancy and has not noticed improvement in urgency. What is the most appropriate action according to STOPP/START criteria?
A. Increase tolterodine dose to 4mg three times daily for better symptom control
B. Continue tolterodine but add finasteride for benign prostatic hyperplasia
C. Stop tolterodine as antimuscarinic drugs worsen bladder outflow obstruction (Correct Answer)
D. Switch tolterodine to solifenacin which has fewer anticholinergic effects
E. Continue tolterodine but reduce tamsulosin dose to minimize interaction
Explanation: ***Stop tolterodine as antimuscarinic drugs worsen bladder outflow obstruction***- Tolterodine is an **antimuscarinic agent** that relaxes the detrusor muscle, which can worsen **bladder outflow obstruction** in patients with **benign prostatic hyperplasia (BPH)**.- The patient's **worsening urinary hesitancy** and lack of improvement in urgency since starting tolterodine clearly indicate an adverse effect, consistent with **STOPP criteria** to avoid anticholinergics in **BPH**.*Increase tolterodine dose to 4mg three times daily for better symptom control*- Increasing the dose of an antimuscarinic in a patient with **BPH** and worsening hesitancy would further inhibit detrusor contraction and increase the risk of **acute urinary retention**.- Since the current dose has not improved urgency and has worsened hesitancy over 3 months, further dose escalation is contraindicated and unsafe.*Continue tolterodine but add finasteride for benign prostatic hyperplasia*- Adding **finasteride**, a 5-alpha reductase inhibitor, primarily reduces prostate size over several months and does not address the immediate **bladder outflow obstruction** exacerbated by tolterodine.- The priority is to discontinue a medication that is actively causing harm or worsening symptoms before introducing new agents.*Switch tolterodine to solifenacin which has fewer anticholinergic effects*- **Solifenacin** is also an **antimuscarinic agent**, sharing the same mechanism of action as tolterodine, and therefore carries similar risks of worsening **bladder outflow obstruction** in BPH.- While solifenacin might have a different side effect profile, it does not resolve the fundamental contraindication of using this drug class in patients with significant **prostatism** according to **STOPP criteria**.*Continue tolterodine but reduce tamsulosin dose to minimize interaction*- **Tamsulosin** is an alpha-blocker used to improve urine flow in **BPH** by relaxing prostatic smooth muscle, directly opposing the effect of bladder outflow obstruction.- Reducing tamsulosin would likely worsen the patient's **bladder outflow obstruction** and increase the risk of urinary retention, contradicting the goal of improving voiding. There's no significant harmful interaction necessitating tamsulosin dose reduction in this context.
Question 67: A 72-year-old woman attends for her annual medication review. She has rheumatoid arthritis, type 2 diabetes, hypertension, and recurrent urinary tract infections. Her current medications include methotrexate 15mg weekly, folic acid 5mg weekly, prednisolone 5mg daily, metformin 1g BD, ramipril 5mg daily, amlodipine 5mg daily, and atorvastatin 40mg at night. She mentions she takes cranberry supplements daily to prevent UTIs. What is the most important medication safety concern to address?
A. Methotrexate should be taken daily rather than weekly with folic acid
B. Prednisolone dose should be taken on alternate days to reduce side effects
C. Metformin and ramipril combination increases risk of lactic acidosis
D. Cranberry supplements may interact with atorvastatin increasing myopathy risk (Correct Answer)
E. Folic acid should be taken on the same day as methotrexate for optimal effect
Explanation: ***Cranberry supplements may interact with atorvastatin increasing myopathy risk*** - **Cranberry products** can inhibit **Cytochrome P450 enzymes** (specifically CYP3A4), which are responsible for the metabolism of **atorvastatin**. - This inhibition leads to increased plasma concentrations of the statin, significantly raising the risk of **statin-induced myopathy** and **rhabdomyolysis**. *Methotrexate should be taken daily rather than weekly with folic acid* - **Methotrexate** must be taken **once weekly** for rheumatoid arthritis; daily dosing is a dangerous error that can lead to fatal **bone marrow suppression**. - The patient's current regimen of 15mg weekly is correct and safe, so this is not a concern to address. *Prednisolone dose should be taken on alternate days to reduce side effects* - **Prednisolone 5mg daily** is a standard, low-dose maintenance therapy for **rheumatoid arthritis** and is generally well-tolerated. - While alternate-day dosing can reduce **HP-axis suppression**, daily dosing is the conventional clinical practice for managing symptomatic RA flare prevention. *Metformin and ramipril combination increases risk of lactic acidosis* - There is no specific direct interaction between **Metformin** and **Ramipril** that increases the risk of **lactic acidosis**. - The primary risk for metformin-induced lactic acidosis is **renal impairment**, which requires monitoring but is not exacerbated specifically by the presence of an ACE inhibitor alone. *Folic acid should be taken on the same day as methotrexate for optimal effect* - **Folic acid** should be taken **at least 24 hours after** the methotrexate dose to avoid reducing its therapeutic efficacy. - Taking it on the same day can function as an antidote, potentially preventing the **methotrexate** from effectively treating the arthritis symptoms.
Question 68: A 67-year-old man with multimorbidity attends for a medication review. He has type 2 diabetes, ischaemic heart disease, hypertension, and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²). He takes 10 regular medications. He reports feeling dizzy on standing and has had two falls in the past month. His sitting blood pressure is 118/68 mmHg, standing blood pressure 95/55 mmHg. His most recent HbA1c is 48 mmol/mol. Which medication class is the highest priority to review and potentially reduce in this clinical scenario?
A. Antihypertensive agents (Correct Answer)
B. Antiplatelet therapy
C. Proton pump inhibitors
D. Statins
E. Metformin
Explanation: ***Antihypertensive agents***
- The patient exhibits symptomatic **orthostatic hypotension**, with a 23 mmHg systolic drop upon standing, which is the direct cause of his reported **dizziness** and **falls**.
- Given his multimorbidity, current polypharmacy, and well-controlled sitting blood pressure, reviewing and reducing antihypertensive medication is the highest priority to improve safety and prevent further injury from falls.
*Antiplatelet therapy*
- **Antiplatelet agents** are crucial for the **secondary prevention** of cardiovascular events in patients with ischaemic heart disease and do not typically induce **orthostatic hypotension**.
- Discontinuing this therapy would significantly increase the risk of serious **thrombotic events** without addressing the patient's immediate fall risk.
*Proton pump inhibitors*
- **Proton pump inhibitors (PPIs)** are used for gastric protection and do not have any direct hemodynamic effects that would contribute to **orthostatic hypotension** or falls.
- While often a target for **deprescribing** in polypharmacy, they are not implicated in the acute symptoms of dizziness and recurrent falls observed.
*Statins*
- **Statins** are essential medications for managing **ischaemic heart disease** to lower cholesterol and reduce cardiovascular risk, and they are not known to cause **orthostatic hypotension**.
- Removing statin therapy would increase the risk of future **cardiovascular events** and would not alleviate the current issue of postural dizziness and falls.
*Metformin*
- **Metformin** is a first-line agent for **type 2 diabetes** and does not typically cause **hypotension** or **orthostatic dizziness**.
- The patient's HbA1c is well-controlled, and Metformin is not responsible for the significant postural blood pressure drop observed.
Question 69: A 70-year-old woman presents for a routine chronic disease review. She has five long-term conditions: type 2 diabetes mellitus, hypertension, osteoarthritis, hypothyroidism, and depression. She takes 9 regular medications and reports good adherence. Her HbA1c is 52 mmol/mol, blood pressure 138/82 mmHg, and she feels generally well. According to current best practice guidance for managing patients with multimorbidity, what is the most appropriate approach to her ongoing care?
A. Refer to secondary care for specialist multimorbidity clinic assessment
B. Focus consultations on single disease targets to optimize each condition
C. Adopt a holistic approach prioritizing patient preferences and treatment burden (Correct Answer)
D. Increase monitoring frequency to monthly reviews given multiple conditions
E. Add additional preventative medications to reduce future complication risk
Explanation: ***Adopt a holistic approach prioritizing patient preferences and treatment burden***
- For patients with **multimorbidity** (the presence of two or more long-term conditions), best practice guidance, such as **NICE NG56**, emphasizes shifting from single-disease frameworks to **patient-centered care**.
- This approach focuses on improving **quality of life** by identifying what matters most to the patient, reducing **polypharmacy**, and managing the collective **treatment burden** of multiple medications.
*Refer to secondary care for specialist multimorbidity clinic assessment*
- Managing multimorbidity is a core function of **Primary Care**; most stable patients do not require specialist clinics for multi-system management.
- Referral is only indicated for highly complex cases where **clinical interactions** between conditions cannot be safely managed in general practice.
*Focus consultations on single disease targets to optimize each condition*
- Following multiple single-disease guidelines can lead to **inappropriate polypharmacy** and contradictory treatment goals in elderly patients.
- Prioritizing **individualized targets** over rigid clinical markers helps avoid over-treatment and reduces the risk of **adverse drug reactions**.
*Increase monitoring frequency to monthly reviews given multiple conditions*
- Frequent monitoring increases the **treatment burden** and can negatively impact the patient's lifestyle and well-being without clear clinical benefit.
- When conditions are **clinically stable** (as indicated by her HbA1c and BP), reviews should be scheduled based on necessity rather than a fixed, high-frequency interval.
*Add additional preventative medications to reduce future complication risk*
- Adding more drugs increases the risk of **non-adherence** and **drug-drug interactions**, which is a significant concern for a patient already taking **9 regular medications**.
- Best practice focuses on **deprescribing** and rationalizing medication rather than reflexively adding preventative agents in the context of high polypharmacy.
Question 70: A 75-year-old man with ischaemic heart disease, heart failure (NYHA class II), type 2 diabetes, COPD, and chronic kidney disease stage 3b takes 11 regular medications. During a comprehensive medication review, you use the Medicines Optimisation principles from the Royal Pharmaceutical Society. You have already ensured he understands why he takes each medicine (Principle 1) and that he chooses medicines based on conversations about what matters to him (Principle 2). You are now addressing whether each medicine is working optimally (Principle 3). His recent blood tests show: HbA1c 64 mmol/mol, eGFR 38 ml/min/1.73m², NT-proBNP 680 ng/L (previously 420 ng/L 6 months ago), and BP 146/88 mmHg. Which single parameter most urgently requires medication optimization?
A. Blood pressure control
B. Glycaemic control
C. Heart failure status (Correct Answer)
D. Proteinuria monitoring
E. Renal function
Explanation: ***Heart failure status***
- The significant rise in **NT-proBNP** from 420 to 680 ng/L indicates **deteriorating heart failure** and an increased risk of hospitalization or mortality.
- **Medicines optimization** (Principle 3) is urgent here to ensure the patient is on the maximal tolerated doses of **prognostic medications** such as ACE inhibitors, beta-blockers, and SGLT2 inhibitors.
*Blood pressure control*
- A blood pressure of **146/88 mmHg** is above the ideal target but does not represent an **acute clinical risk** compared to heart failure progression.
- Blood pressure will often improve as a secondary benefit when **heart failure medications** (like SGLT2 inhibitors or RAAS blockers) are optimized.
*Glycaemic control*
- An **HbA1c of 64 mmol/mol** is slightly above the typical target of 58 mmol/mol but does not constitute a **glycaemic emergency**.
- For a 75-year-old with **multimorbidity**, overly tight glycaemic control is often avoided to prevent the high risk of **hypoglycaemia**.
*Proteinuria monitoring*
- While monitoring for **proteinuria** is a standard part of **CKD management**, it is a screening/staging tool rather than a parameter needing urgent medication change in this context.
- The current clinical focus must remain on the **hemodynamic stability** indicated by the rising cardiac biomarkers.
*Renal function*
- An **eGFR of 38 ml/min/1.73m²** matches the patient's known diagnosis of **CKD stage 3b** and appears stable.
- While renal function must be monitored when adjusting heart failure drugs, it is the **rising NT-proBNP**, not the baseline eGFR, that triggers the need for immediate intervention.
